readthroughSign in
Jul 23, 2026Weekly roundup

Bayer completes Phase 1 nurandociguat bioavailability study; VERIFICATION trial recruits

A Bayer-sponsored nurandociguat tablet comparison study has wrapped up, while a West China Hospital trial testing vericiguat for aortic valve calcification continues enrolling.

Bayer closed out an early-stage pharmacokinetics study while a collaborator-sponsored cardiovascular trial remains active.

  • Bayer's Phase 1 study comparing a new nurandociguat tablet formulation to an older one, and testing food effects, is now completed. The trial enrolled 16 healthy participants and used a randomized crossover design1, with an actual primary completion date of 2026-10-12.
  • West China Hospital's VERIFICATION study (NCT07715279), with Bayer as a collaborator, continues recruiting to test whether vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, can slow the progression of mild-to-moderate CAVS2. The trial plans to enroll approximately 238 participants across roughly 19 hospitals in China2, with estimated primary completion on 2029-10-31.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.